At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® 9 μg, Compared With Serevent® Diskus® 50 μg.
In Brief
A Phase 2 clinical trial evaluating Formoterol, Salmeterol, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 109 participants across 17 sites in 3 countries.
Detailed Summary
* Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced Expiratory Volume in 1 second (FEV1) measured by spirometry 5 minutes postdose. * Secondary efficacy variables: Average FEV1 during the first 15 minutes (area under the FEV1 curve from 0 to 15 minutes), Average FEV1 during 120 minutes (area under the FEV1 curve from 0 to 120 minutes)
Study Details
Timeline
Interventions
Formoterol Turbuhaler 9 μg and Placebo Diskus
Salmeterol Diskus 50 μg and Placebo Turbuhaler
Placebo Diskus and Placebo Turbuhaler